Longevity is, increasingly, big business. Advances in healthcare technology and AI have prompted prominent medical professionals and individual investors to think about how people can live longer, healthier lives. Although still relatively young, the longevity industry is expected to nearly triple in size from 2025 to 2035.
Longevity is still very much a niche play for investors, and there are few ways to get directly involved outside of positions in a few individual biotech firms. Investors who take a long view of the industry—or those who aren't sure how to make a specific bet on one or more companies, given the emerging nature of the longevity space—may choose an exchange-traded fund (ETF).
The ETFs below provide varying degrees of exposure to long-lived companies, from the broadest to the narrowest.
XBI: A Comprehensive Biotech Approach
SPDR S&P Biotech ETF today
SPDR S&P Biotech ETF
As of 06/5/2026 04:10 PM Eastern
- 52 week interval
- $80.90
▼
$139.19
- Dividend Yield
- 0.34%
- Assets Under Administration
- $7.86 billion
Company rating SPDR S&P Biotech ETF NYSEARCA: XBI is a traditional biotech ETF with a basket of nearly 150 US biotech companies across markets.
The fund is popular among investors, with about $8 billion in assets under management and a one-month trading average of close to $8.5 million.
Biotech companies tend to carry a good amount of risk, as many firms in this space are working to develop commercial products. As such, the bulk of XBI's portfolio is small firms in the mid-cap and small-cap range.
It also balances its positions evenly, ensuring that no single holding represents more than 1.8% of the portfolio. This can help spread this risk, although it may also prevent XBI from achieving large rallies in individual names as well.
XBI is not exactly a fund focused on long-term health, but all the companies in the basket are in the healthcare space and are developing new treatments and products to treat and deal with various diseases.
Its return of about 5.5% year-to-date (YTD) is relatively slow compared to the broader market. However, looking at the last 12 months, the fund has outperformed with a return of over 50%. It paid a dividend of €0.34 per share last term and an annual yield of 0.35 %.
SPDR S&P Biotech ETF (XBI) price chart for Monday, June 8, 2026
BMED: Health Innovation for Cutting Edge Technology
Shares Health Innovation Active ETF today
iShares Health Innovation Active ETF
As of 06/5/2026 04:10 PM Eastern
- 52 week interval
- $24.20
▼
$32.19
- Assets Under Administration
- $10.24 million
Taking an active approach, the iShares Health Innovation Active ETF NYSEARCA: BMED does not track an index, but seeks to compile a manager-selected list of innovative companies from across the healthcare sector.
As an actively managed fund, investors can expect BMED to carry a high annual fee, and in this case, the average expense is 0.55%.
BMED's portfolio is quite small compared to XBI, with around 50 positions of various sizes. The largest shares in the fund's basket come in at more than 5% each, so this ETF isn't nearly as diverse as many other offerings in the space.
BMED is also not directly linked to the longevity industry, although it has several biotech and other names focused on this space.
So far in 2026, BMED management has significantly underperformed the market. However, fortunately, as a fully managed fund this ETF is not subject to quarterly re-registration but can change its portfolio at any time.
iShares Health Innovation Active ETF (BMED) price chart for Monday, June 8, 2026
AGNG: Focused on Improving and Extending the Lives of Older People
Global X Aging Population ETF today
Global X Aging Population ETF
As of 06/5/2026 03:59 PM Eastern
- 52 week interval
- $31.14
▼
$39.48
- Dividend Yield
- 0.89%
- Assets Under Administration
- $81.49 million
Global X Aging Population ETF NASDAQ: AGNG perhaps the best ETF to focus on the longevity unit.
Taking a market-cap-weighted approach to portfolio construction, the fund tracks an index of companies that aim to improve and extend the lives of seniors.
This presents a basket of about 90 companies in the medical devices, life sciences, biotech, and pharmaceutical industries, and with a broad geographic focus on developed markets.
One trade-off for AGNG's theme is a small asset base: the fund has $81 million in assets under management and similarly low trading volumes, so liquidity is a factor investors should keep in mind. It also has a higher expense ratio than other investors can afford, at 0.50%.
Like BMED, the strategy has not yet paid off in returns by 2026, so investors may prefer to think of AGNG as a long-term bet on the industry. Its dividend payout helps reduce the sweet spot on offer, although the 0.89% yield is probably not enough to make investors consider AGNG as a dividend play sec.
Global X Aging Population ETF (AGNG) price chart for Monday, June 8, 2026
Before you consider the SPDR S&P Biotech ETF, you'll want to hear this.
MarketBeat tracks Wall Street's top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and the SPDR S&P Biotech ETF was not on the list.
Although SPDR S&P Biotech ETF currently has a hold rating among analysts, top analysts believe these five stocks are the best.
View Five Stocks Here
Discover the 10 Best Stocks to Go for 2026 and secure a reliable income in uncertain markets. Download the report now to identify high dividend payers and avoid common dividend pitfalls.
Get This Free Report
